Abstract:
Objective Dendritic cells (DC) can be divided into two subgroups based on the markers and functions: myeloid-DC (DC1) and plasmacytoid-DC (DC2). This study evaluated the clinical significance of the proportion of DC subgroups in the peripheral blood of lung cancer patients before and after GVAX vaccineation.
Methods Seventy-four patients with lung cancer were enrolled in the study. Flow cytometry was used to detect the proportion of DCs and lymphocyte subgroups before and after GVAX vaccination. The correlation of DCs with serum markers and immune cells was tested. The Kaplan-Meier was used to analyze the correlations between DCs and survival of patients.
Results There was no significant change in the proportion of DCs after GVAX vaccination. The proportion of DCs was higher in the group with elevated levels of neuron-specific enolase (NSE) than in normal controls. A negative correlation was observed between the proportion of DC2 post-GVAX vaccination and the proportion of Treg pre-GVAX vaccination. For patients with early lung cancer, those with a proportion of DC2 below the mean value after vaccination had better overall survival compared with those with a proportion of DC2 greater than the mean value.
Conclusion A low proportion of DC2 after GVAX vaccination is a predictor of better prognosis for patients who received GVAX vaccination. DC2 proportion post-GVAX vaccination may have a correlation with the proportion of Treg in the peripheral blood pre-GVAX vaccination.
下载: